AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22529273 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard perioperative care with intraoperative morphine
Number of subjects: 194
Study 22529995 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI FLAIR images in ALS patients
Number of subjects: 38
Study 22529995 — intervention group
Group type: EXPERIMENTAL
Intervention: 7T MRI T(2)(*)-weighted gradient echo imaging
Number of subjects: 38
Study 22529995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological studies
Number of subjects: 38
Study 22529995 — intervention group
Group type: COMPARATOR
Intervention: 3T MRI FLAIR images
Number of subjects: 38
Study 22531596 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB scaffold implantation
Number of subjects: 83
Study 22531869 — intervention group
Group type: EXPERIMENTAL
Intervention: Single complete compression ultrasonography
Number of subjects: 210
Study 22531869 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative single complete compression ultrasonography result
Number of subjects: 210
Study 22533698 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV) or ganciclovir (GCV) prophylaxis (n = 20)
Number of subjects: 114
Study 22533698 — intervention group
Group type: COMPARATOR
Intervention: No chemoprophylaxis (n = 8)
Number of subjects: 114
Study 22533698 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV) or ganciclovir (GCV) prophylaxis
Number of subjects: 114
Study 22534421 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 39
Study 22535636 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention (n=24)
Number of subjects: 52
Study 22535636 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic intervention (n=11)
Number of subjects: 52
Study 22535761 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake (red meat, processed meat, fish, poultry, heme iron, nitrite, nitrate, animal fat, protein)
Number of subjects: 492186
Study 22535761 — intervention group
Group type: EXPERIMENTAL
Intervention: MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline)
Number of subjects: 492186
Study 22535761 — intervention group
Group type: EXPERIMENTAL
Intervention: DiMeIQx (2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline)
Number of subjects: 492186
Study 22536072 — intervention group
Group type: EXPERIMENTAL
Intervention: German physicians' attitudes towards risk factor control based on the 2007 European guidelines on cardiovascular disease prevention.
Number of subjects: 7641
Study 22536072 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor control rates in German patients.
Number of subjects: 7641
Study 22536072 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of risk engines by German physicians.
Number of subjects: 7641
Study 22536072 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of ESC guidelines for German physicians.
Number of subjects: 7641
Study 22536884 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 22536884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22536884 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin vs Placebo
Number of subjects: 0
Study 22537054 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with central obesity
Number of subjects: 595
Study 22537054 — intervention group
Group type: COMPARATOR
Intervention: Subjects without central obesity
Number of subjects: 595
Study 22537162 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFIRI
Number of subjects: 71
Study 22537906 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular model for predicting bone metastasis based on CXCR4, BSP, OPN, and BMP4.
Number of subjects: 105
Study 22537906 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular model validated in another 40 patients with stage III NSCLC.
Number of subjects: 105
Study 22537988 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose MenC vaccine (given at 2 and 4 months)
Number of subjects: 3
Study 22537988 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose MenC vaccine (given at 2 months)
Number of subjects: 3
Study 22537988 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated infants
Number of subjects: 3
Study 22537988 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects after the 12 month MenC dose
Number of subjects: 3
Study 22539091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasisulam sodium (420 μg/mL) administered intravenously on day 1 of 21-day cycles
Number of subjects: 63
Study 22539478 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 550
Study 22539478 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 550
Study 22540954 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg/kg intravenous artesunate
Number of subjects: 14
Study 22541066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus 3-AP (96 mg/m(2) for 4 days, with cisplatin at 25 mg/m(2) on days 2 and 3)
Number of subjects: 6
Study 22541066 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 6
Study 22541066 — intervention group
Group type: COMPARATOR
Intervention: 3-AP preceding cisplatin exposure
Number of subjects: 6
Study 22541066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus 3-AP
Number of subjects: 6
Study 22541066 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-AP (96 mg/m(2))
Number of subjects: 6
Study 22541178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF) energy surgical ablation
Number of subjects: 118
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprosthesis usage
Number of subjects: 15
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum standing time
Number of subjects: 15
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support
Number of subjects: 15
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee strength
Number of subjects: 15
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee fatigue index
Number of subjects: 15
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode stability
Number of subjects: 15
Study 22541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Component survivability
Number of subjects: 15
Study 22541602 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual HbA(1c) targets
Number of subjects: 759
Study 22541602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-patient partnership
Number of subjects: 759
Study 22541602 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert T2D guidelines
Number of subjects: 759
Study 22541660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with intraocular lens implantation
Number of subjects: 100
Study 22541660 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery with intact posterior capsules, manual posterior capsulorrhexis without anterior limbal vitrectomy, and anterior limbal vitrectomy
Number of subjects: 100
Study 22542159 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infusion of bone marrow mesenchymal stem cells (BMMSCs)
Number of subjects: 0
Study 22542159 — intervention group
Group type: COMPARATOR
Intervention: FASL(-/-) BMMSCs
Number of subjects: 0
Study 22542580 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 30
Study 22542580 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 30
Study 22543217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive planning (replanning of radiation therapy)
Number of subjects: 44
Study 22543217 — intervention group
Group type: COMPARATOR
Intervention: Nonadaptive planning (original treatment plans)
Number of subjects: 44
Study 22543217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive planning
Number of subjects: 44
Study 22543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marathon ECG parameters
Number of subjects: 198
Study 22543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marathon serum magnesium levels
Number of subjects: 198
Study 22543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marathon serum potassium levels
Number of subjects: 198
Study 22543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marathon interleukin 6 levels
Number of subjects: 198
Study 22544699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (rATG) and cyclosporine
Number of subjects: 35
Study 22544699 — intervention group
Group type: COMPARATOR
Intervention: Horse ATG (hATG) and cyclosporine
Number of subjects: 35
Study 22544699 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG
Number of subjects: 35
Study 22544699 — intervention group
Group type: COMPARATOR
Intervention: hATG
Number of subjects: 35
Study 22544910 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-ups using Merlin@home and Merlin.net
Number of subjects: 200
Study 22544910 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulatory follow-ups
Number of subjects: 200
Study 22545575 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz® videolaryngoscope (SVL)
Number of subjects: 10
Study 22545575 — intervention group
Group type: COMPARATOR
Intervention: Airtraq® Optical laryngoscope (AOL)
Number of subjects: 10
Study 22545881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventana fenestrated stent-graft system
Number of subjects: 2
Study 22545887 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft with the Captivia Delivery System
Number of subjects: 100
Study 22546242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat 2000 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Number of subjects: 19
Study 22546242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat 2500 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Number of subjects: 19
Study 22547151 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-WT-HSCT
Number of subjects: 100
Study 22547151 — intervention group
Group type: COMPARATOR
Intervention: WT-HSCT
Number of subjects: 100
Study 22547151 — intervention group
Group type: COMPARATOR
Intervention: LV-IIIA-HSCT
Number of subjects: 100
Study 22547163 — intervention group
Group type: EXPERIMENTAL
Intervention: Salirasib 200-800 mg orally (PO) twice daily (bid) for 21 days every 28 days in combination with gemcitabine.
Number of subjects: 19
Study 22547163 — intervention group
Group type: EXPERIMENTAL
Intervention: Salirasib administered alone and in combination with gemcitabine.
Number of subjects: 19
Study 22547163 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (standard dose schedule).
Number of subjects: 19
Study 22547579 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC grafts containing dimethyl sulfoxide (DMSO) and lysed red blood cells (RBCs)
Number of subjects: 60
Study 22547579 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC grafts with no DMSO and fresh RBCs
Number of subjects: 60
Study 22547579 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC grafts with DMSO and no RBCs
Number of subjects: 60
Study 22547579 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 22547579 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 22547583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic plasmatherapy
Number of subjects: 42
Study 22547583 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 42
Study 22550086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulfate 6.3 ± 0.87 mg/kg/d for 8 weeks
Number of subjects: 17
Study 22551422 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT (25 × 2 Gy) and carbon ion boost (8 × 3 GyE)
Number of subjects: 29
Study 22554343 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS plus bevacizumab (S-1 40-60 mg twice daily on Days 1 to 14, irinotecan 100 mg/m² and bevacizumab 5 mg/kg on Days 1 and 15 of a 28-day cycle)
Number of subjects: 52
Study 22554343 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS plus bevacizumab
Number of subjects: 52
Study 22554401 — intervention group
Group type: EXPERIMENTAL
Intervention: FAQLQ-PF (Parent's form)
Number of subjects: 94
Study 22554401 — intervention group
Group type: EXPERIMENTAL
Intervention: FAQLQ-CF (Children's form)
Number of subjects: 94
Study 22554417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) genotype functional class with minimal CFTR function
Number of subjects: 889
Study 22554417 — intervention group
Group type: COMPARATOR
Intervention: Newborn screening
Number of subjects: 889
Study 22554417 — intervention group
Group type: COMPARATOR
Intervention: Modifiable risk factors (cigarette smoke, hot tub use, breastfeeding, daycare)
Number of subjects: 889
Study 22555165 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir-based HAART
Number of subjects: 17
Study 22555568 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-worn device (AposTherapy)
Number of subjects: 34
Study 22555974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with nonmyeloablative chemotherapy and TBI
Number of subjects: 4
Study 22555974 — intervention group
Group type: COMPARATOR
Intervention: Adoptive immunotherapy with nonmyeloablative chemotherapy
Number of subjects: 4
Study 22555974 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 administration
Number of subjects: 4
Study 22555973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carfilzomib 20 mg/m(2) for all treatment cycles (Cohort 1)
Number of subjects: 129
Study 22555973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carfilzomib 20 mg/m(2) for cycle 1 and then 27 mg/m(2) for all subsequent cycles (Cohort 2)
Number of subjects: 129
Study 22556025 — intervention group
Group type: EXPERIMENTAL
Intervention: Chartis™ Pulmonary Assessment System
Number of subjects: 80
Study 22556318 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON TB Gold In-Tube assay (QFT-GIT) monthly for 1 year
Number of subjects: 49
Study 22558076 — intervention group
Group type: EXPERIMENTAL
Intervention: SMN2 copy number, levels of full-length SMN2 transcripts, SMN protein levels in SMA subjects
Number of subjects: 108
Study 22558076 — intervention group
Group type: EXPERIMENTAL
Intervention: SMN expression measures (transcript and protein)
Number of subjects: 108
Study 22558076 — intervention group
Group type: EXPERIMENTAL
Intervention: SMN2 copy number, levels of transcript and protein
Number of subjects: 108
Study 22558076 — intervention group
Group type: EXPERIMENTAL
Intervention: SMN expression in blood
Number of subjects: 108
Study 22558076 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length SMN transcript abundance
Number of subjects: 108
Study 22558101 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2) administered intravenously every 3 weeks at escalating doses (0.01 to 0.09 mg/kg)
Number of subjects: 31
Study 22558101 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2)
Number of subjects: 31
Study 22558154 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate biomarkers (proteins and metabolites)
Number of subjects: 108
Study 22558154 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study 22558154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcripts
Number of subjects: 108
Study 22558168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized studies
Number of subjects: 0
Study 22558168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized crossover studies
Number of subjects: 0
Study 22559192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency deep TMS (1 Hz for 10 min) applied over the left temporoparietal cortex, 10 daily treatment sessions at 110% of the motor threshold.
Number of subjects: 18
Study 22559192 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo) according to patient randomization.
Number of subjects: 18
Study 22560391 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD)
Number of subjects: 698
Study 22560524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures (weight, hip circumference, waist circumference, waist-hip ratio, waist-height ratio, weight-height ratio, body adiposity index, body mass index)
Number of subjects: 2037
Study 22560524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric variables
Number of subjects: 2037
Study 22560524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures
Number of subjects: 2037
Study 22560543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thoracic radiation (61.2 Gy over 5 weeks, daily 1.8-Gy fractions on days 1-22, then twice-daily 1.8-Gy fractions on days 23-33) with concurrent chemotherapy (Cisplatin 60 mg/m² IV on day 1, Etoposide 120 mg/m² IV on days 1-3 and days 22-24).
Number of subjects: 72
Study 22560543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thoracic radiation with concurrent chemotherapy.
Number of subjects: 72
Study 22560543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation offered to patients who achieved complete response.
Number of subjects: 72
Study 22562047 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major depressive disorder (MDD)
Number of subjects: 46
Study 22562047 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 46
Study 22562290 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α serum levels measured before, one and 6 days after PCI
Number of subjects: 42
Study 22562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size quantified by late gadolinium enhancement cardiovascular magnetic resonance imaging (LGE-CMR) on day six
Number of subjects: 42
Study 22562517 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal visual implant
Number of subjects: 10
Study 22563089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2) infused weekly on days 56, 63, 70, and 77 after transplantation)
Number of subjects: 35
Study 22563089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 35
Study 22563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 22563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 22563743 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 22564202 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a 16-session GCBT-D intervention (n = 140)
Number of subjects: 299
Study 22564202 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 159)
Number of subjects: 299
Study 22565291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotic prophylaxis (10.5% of women received this intervention)
Number of subjects: 8129
Study 22565291 — intervention group
Group type: COMPARATOR
Intervention: Preterm delivery
Number of subjects: 8129
Study 22565291 — intervention group
Group type: COMPARATOR
Intervention: Low birth weight (<1500 g)
Number of subjects: 8129
Study 22565291 — intervention group
Group type: COMPARATOR
Intervention: Meconium-stained amniotic fluid (MSAF)
Number of subjects: 8129
Study 22565291 — intervention group
Group type: COMPARATOR
Intervention: First birth
Number of subjects: 8129
Study 22566312 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 levels in patients with stress hyperglycaemia requiring vasoactive support
Number of subjects: 60
Study 22566312 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemia levels
Number of subjects: 60
Study 22566312 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 levels
Number of subjects: 60
Study 22566420 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-facilitated screening and provider brief advice (cSBA)
Number of subjects: 2685
Study 22566420 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2685
Study 22566506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.15-0.30 mg/kg per day in 2 divided oral doses) and prednisone (60 mg per day, tapered off during 1 to 4 weeks)
Number of subjects: 26
Study 22566506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisone
Number of subjects: 26
Study 22566506 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 26
Study 22566605 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m² intravenously on days 1-10) plus bortezomib (escalated up to the target 1.3 mg/m² on days 5, 8, 12, and 15)
Number of subjects: 19
Study 22566747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW)
Number of subjects: 25000
Study 22566747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 25000
Study 22566747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-adherence insulin
Number of subjects: 25000
Study 22568777 — intervention group
Group type: EXPERIMENTAL
Intervention: DIGS software insulin dosage adjustments
Number of subjects: 46
Study 22569039 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12
Study 22569039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22569123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) 20 Gy with Intrabeam system/Carl Zeiss
Number of subjects: 540
Study 22569123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 540
Study 22570147 — intervention group
Group type: EXPERIMENTAL
Intervention: Efatutazone at doses ranging from 0.10 to 1.15 mg PO twice daily for 6 weeks
Number of subjects: 31
Study 22570147 — intervention group
Group type: EXPERIMENTAL
Intervention: Efatutazone at the recommended phase 2 dose of 0.5 mg PO twice daily
Number of subjects: 31
Study 22571443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution MRI with local anaesthetics injected
Number of subjects: 18
Study 22571443 — intervention group
Group type: COMPARATOR
Intervention: High-resolution MRI without local anaesthetics injected
Number of subjects: 18
Study 22572602 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multisector approach (Millennium Villages project)
Number of subjects: 0